Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2008

View Archived Issues

HSPA12B, a novel target for antiangiogenesis therapy

Novel monoclonal antibodies show low tendency for bleeding in models of arterial thrombosis

Titan presents positive phase III results for Probuphine in opioid addiction

FDA grants orphan drug designation to Polyphenon's Polyphenon E for CLL

Allergan to initiate phase I clinical development of retargeted endopeptidase drug candidate

CHMP recommends refusal of Santhera's MAA for Sovrima in Friedreich's ataxia

FDA issues not approvable letter in response to Vanda's NDA for iloperidone in schizophrenia

Anticoagulant Xarelto recommended for approval in E.U.; NDA submitted in U.S.

Chinese SFDA approves Nexavar for HCC

No improvement with BioBypass gene therapy in patients with refractory ischemia

A Ginkgo biloba extract improves cognitive and neuropsychiatric symptoms in AD and vascular dementia

Clinical results with bapineuzumab immunotherapy in mild to moderate AD reported at ICAD

GPC Biotech reports withdrawal of MAA for satraplatin in prostate cancer

FDA issues not approvable letter to Eisai for sedative-hypnotic agent fospropofol disodium

SuperArray Bioscience changes name to SABiosciences

Merck & Co places development hold on HIV protease inhibitor PPL-100

CHMP recommends marketing authorization for GSK's prepandemic influenza vaccine

Sanofi pasteur agrees terms of cash offer for share capital of Acambis

Arpida submits MAA to the EMEA for iclaprim in cSSTI

Roche submits application to EMEA to extend label for Avastin in breast cancer

MediGene's Oracea receives marketing authorization in Europe

Nuvelo commences phase I NU-206 trial in healthy volunteers

European Commission approves Schering-Plough's Bridion

Novel antidiabetic agents claimed in recent patents

Advances in development of agents for neurological disorders documented in recent patents

FDA issues not approvable letter to UCB for Vimpat in diabetic neuropathic pain

Novel Rho kinase inhibitors developed at sanofi-aventis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...